Research
Hormonal
Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).
Tirzepatide may help reduce cardiovascular risks in obese patients.
StrongSupportsmedium confidence
Tirzepatide also reduced the risk of MACEs (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).
Why this rating
The study involves a large sample size with propensity score matching.
Source
Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study
Jheng‐Yan Wu et al. · Diabetes Obesity and Metabolism · 2025
cohort · n=168968Cited 14×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →